Immuron & Monash University to develop a Clostridium difficile therapeutic
C. difficile infections have become a major medical problem especially in hospitals and long-term care facilities because the bacteria produce toxins that cause inflammation of the colon, causing severe diarrhoea and, in serious cases, death. An estimated 28,000 people die each year from these infections in the USA alone.
Monash University has received government funding through an ARC Linkage grant. As is typical with these grants, Immuron and Monash will together own the technology to be generated and Immuron has the exclusive global commercialisation rights.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.